---
title: Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles
nct_id: NCT00734786
overall_status: WITHDRAWN
phase: PHASE1, PHASE2
sponsor: Phytotox SA
study_type: INTERVENTIONAL
primary_condition: Facial Wrinkles
countries: Argentina
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00734786.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00734786"
ct_last_update_post_date: 2008-08-25
last_seen_at: "2026-05-12T06:18:28.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles

**Official Title:** Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles. Study # CLN 08-003.

**NCT ID:** [NCT00734786](https://clinicaltrials.gov/study/NCT00734786)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Study cancelled.
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 15
- **Lead Sponsor:** Phytotox SA
- **Conditions:** Facial Wrinkles
- **Start Date:** 2008-08
- **Completion Date:** 2008-09
- **CT.gov Last Update:** 2008-08-25

## Brief Summary

The main objective of the trial is to determine whether the current topical formulation of GTX 2/3 reduces the wrinkling of the skin (crow's feet) after a single application

Other evaluation criteria include: safety assessment and local tolerance, depth of facial wrinkles (video microscopy imaging).

## Detailed Description

This is a single volunteer group study. Each volunteer will be her own control. A volunteer will receive the active product containing cream on one side of her face and will receive the placebo cream on the other side.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 60 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Women with no bearing-child potential or with adequate birth control method.
* Volunteers between 30 to 60 years of age.
* Subjects with bilateral crow's feet wrinkles.
* Regular user of cosmetic products, willing and able to comply with the study objectives.
* Signed informed consent.

Exclusion Criteria:

* Any medical condition or any use of a medication that could modify the study results (e.g.: NSAIDs, immunosuppressant drugs, insulin...).
* Any other significant medical condition (e.g.: diabetes mellitus, heart disease, liver disease...).
* Any other condition that in the investigator's opinion could not be appropriate with the participation in this trial.
* Any health condition that could affect the evaluation of study parameters.
* Acute or chronic skin disease.
* History of allergic reaction to cosmetic compounds.
* Pregnancy, planned pregnancy or breast-feeding.
* Allergy to shellfish, fish or sea product (seaweed).
* Known or suspected hypersensitivity to any of the study product compounds.
* Participation in another clinical trial within 30 days previous to enrolment.
* Known or suspected alcohol or drug abuse.
```

## Arms

- **2** (PLACEBO_COMPARATOR) — Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.

## Interventions

- **Wrinkle cream application** (OTHER) — Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.

## Primary Outcomes

- **Depth of facial wrinkles** _(time frame: 24 hours)_

## Secondary Outcomes

- **Local and general tolerance** _(time frame: 1day)_

## Locations (1)

- CLAIM, Buenos Aires, Buenos Aires F.D., Argentina

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.claim|buenos aires|buenos aires f.d.|argentina` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00734786.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00734786*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*